Dr. Alberto Lleó is the director of the Neurology Department at Hospital de la Santa Creu i Sant Pau.
After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona. After that, he continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.
In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias, with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.
Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.
Recent Publications
- Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum. Goossens, J, Cervantes González, A, Dewit, N et al. Alzheimers Res Ther 2023PMID:37898760
- Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study. Guillén, N, Contador, J, Buongiorno, M et al. Eur Arch Psychiatry Clin Neurosci 2023PMID:37898567
- Association of Blood-Based DNA Methylation Markers With Late-Onset Alzheimer Disease: A Potential Diagnostic Approach. Santamaria, BA, Corroza, J, Sánchez-Ruiz de Gordoa, J et al. Neurology 2023PMID:37827850
- Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning. Neumann, A, Ohlei, O, Küçükali, F et al. Genome Med 2023PMID:37794492
- CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease. Del Campo, M, Vermunt, L, Peeters, CFW et al. Nat Commun 2023PMID:37704597
- Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer's disease pathology. Ashton, NJ, Brum, WS, Di Molfetta, G et al. medRxiv 2023PMID:37502842
- Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross-platform validation study. Hok-A-Hin, YS, Bolsewig, K, Ruiters, DN et al. Alzheimers Dement (Amst) 2023PMID:37502019
- Synaptic oligomeric tau in Alzheimer's disease - A potential culprit in the spread of tau pathology through the brain. Colom-Cadena, M, Davies, C, Sirisi, S et al. Neuron 2023PMID:37192625
- Multifocal Transcranial Direct Current Stimulation in Primary Progressive Aphasia Does Not Provide a Clinical Benefit Over Speech Therapy. Borrego-Écija, S, Montagut, N, Martín-Trias, P et al. J Alzheimers Dis 2023PMID:37182884
- Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Zhu, N, Santos-Santos, M, Illán-Gala, I et al. Transl Neurodegener 2023PMID:37158972
- CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Del Campo, M, Peeters, CFW, Johnson, ECB et al. Nat Aging 2022PMID:37118088
- Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer's disease. Mansilla, A, Canyelles, M, Ferrer, R et al. Clin Chem Lab Med 2023PMID:37083158
- Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome. Iulita, MF, Bejanin, A, Vilaplana, E et al. Brain Commun 2023PMID:37056479
- Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndrome. Videla, L, Benejam, B, Carmona-Iragui, M et al. Alzheimers Dement 2023PMID:37038748
- Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome. Rozalem Aranha, M, Iulita, MF, Montal, V et al. Alzheimers Dement 2023PMID:37021589